Jubilant Pharmova Ltd reported a sharp financial turnaround in the fourth quarter ended March 31, 2025, posting a consolidated net profit of Rs. 151.3 crore, reversing a loss of Rs. 61.8 crore from the same period last year. The company’s revenue and profitability saw robust growth both quarterly and annually, reflecting operational efficiency and strategic execution. For the full fiscal year, net profit surged to Rs. 836.3 crore—an exponential rise from Rs. 72.7 crore in FY24. With strong earnings and improved margins, the board has proposed a final dividend of Rs.